Literature DB >> 7480390

No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone.

A L Nordström1, L Farde, L Eriksson, C Halldin.   

Abstract

The dopamine hypothesis of schizophrenia received strong support when a two- to three-fold elevation of D2 receptor densities was demonstrated by positron emission tomography (PET) and [11C]N-methylspiperone ([11C]NMSP). In the present study, the reproducibility of this finding was examined by application of a similar method in seven normal comparison subjects and seven neuroleptic-naive schizophrenic patients examined by PET before and after administration of haloperidol, 7.5 mg. After haloperidol, the specific binding of [11C]NMSP was reduced by 80-90%, resulting in a signal-to-noise ratio that was unfavorably low for reliable quantification. No significant difference was found between normal subjects and patients in a descriptive analysis of the time-activity curves or in a nonequilibrium graphical determination of D2 receptor densities in the basal ganglia. The results are consistent with those of a previous quantitative PET study of [11C]raclopride binding, which showed normal densities of D2 receptors in the striatum of neuroleptic-naive schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480390     DOI: 10.1016/0925-4927(95)02732-d

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  18 in total

1.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.

Authors:  Philip Seeman; David Weinshenker; Remi Quirion; Lalit K Srivastava; Sanjeev K Bhardwaj; David K Grandy; Richard T Premont; Tatyana D Sotnikova; Patricia Boksa; Mufida El-Ghundi; Brian F O'dowd; Susan R George; Melissa L Perreault; Pekka T Männistö; Siobhan Robinson; Richard D Palmiter; Teresa Tallerico
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  A search for association between schizophrenia and dopamine-related alleles.

Authors:  E Jönsson; S Brené; T Geijer; L Terenius; A Tylec; M L Persson; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 4.  Radioligands for brain 5-HT2 receptor imaging in vivo: why do we need them?

Authors:  G F Busatto
Journal:  Eur J Nucl Med       Date:  1996-08

Review 5.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

Review 6.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

7.  Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.

Authors:  Ivonne Suridjan; Pablo Rusjan; Jean Addington; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  J Psychiatry Neurosci       Date:  2013-03       Impact factor: 6.186

8.  Striatal dopamine receptor plasticity in neurotensin deficient mice.

Authors:  Lucy G Chastain; Hongyan Qu; Chase H Bourke; P Michael Iuvone; Paul R Dobner; Charles B Nemeroff; Becky Kinkead
Journal:  Behav Brain Res       Date:  2014-11-15       Impact factor: 3.332

9.  The biochemical womb of schizophrenia: A review.

Authors:  N Gaur; S Gautam; M Gaur; P Sharma; G Dadheech; S Mishra
Journal:  Indian J Clin Biochem       Date:  2008-12-20

10.  123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia.

Authors:  Hans Sjøholm; Trond Bratlid; Johan Sundsfjord
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.